OmniAb Inc.
$ 2.03
-0.49%
24 Jul - close price
- Market Cap 324,739,000 USD
- Current Price $ 2.03
- High / Low $ 2.12 / 2.02
- Stock P/E N/A
- Book Value 1.81
- EPS -0.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.20 %
- 52 Week High 3.12
- 52 Week Low 1.30
About
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology enables the rapid identification and optimization of effective therapies across various disease areas, thereby enhancing the likelihood of successful clinical outcomes. By establishing strategic partnerships and collaborations, OmniAb streamlines its drug development processes and improves access to groundbreaking treatments. Supported by a seasoned leadership team and a robust pipeline of product candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Analyst Target Price
$7.33
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-03-04 | 2025-11-04 | 2025-08-06 | 2025-05-08 | 2025-03-18 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-09 |
| Reported EPS | -0.05 | -0.06 | -0.11 | -0.14 | -0.15 | -0.17 | -0.12 | -0.16 | -0.13 | -0.19 | -0.14 | -0.16 |
| Estimated EPS | -0.11 | -0.1 | -0.0875 | -0.14 | -0.15 | -0.17 | -0.0967 | -0.14 | -0.17 | -0.16 | -0.15 | -0.13 |
| Surprise | 0.06 | 0.04 | -0.0225 | 0 | 0 | 0 | -0.0233 | -0.02 | 0.04 | -0.03 | 0.01 | -0.03 |
| Surprise Percentage | 54.5455% | 40% | -25.7143% | 0% | 0% | 0% | -24.0951% | -14.2857% | 23.5294% | -18.75% | 6.6667% | -23.0769% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OABI
2026-08-07 10:40:30
OmniAb (NASDAQ: OABI) reported strong Q2 2026 results, with revenue increasing to $13.4 million from $3.9 million year over year, primarily driven by partner milestone revenue, and a narrowed net loss of $5.9 million. The company raised its 2026 guidance, forecasting revenue between $32 million and $36 million, and highlighted significant progress in its partnered pipeline with 425 active programs and new clinical entrants. OmniAb also emphasized the potential of its xPloration platform and its genetically engineered chicken antibody discovery technologies in driving future growth and revenue diversification.
2026-08-07 10:40:30
OmniAb, Inc. reported strong second-quarter 2026 financial results, with revenue significantly increasing to $13.4 million, driven by milestone revenue and growth in xPloration. The company raised its full-year 2026 revenue and cash outlook, expecting revenue between $32 million and $36 million. OmniAb also highlighted significant progress in partner programs, including advancements in clinical trials for several therapeutic candidates and the appointment of a new Chief Operating Officer.
2026-08-07 09:40:30
This article provides a technical analysis of OmniAb Inc (OABI), detailing its current price momentum, support and resistance levels, and various technical indicator readings. The stock is currently trading between a resistance level of 2.43 and a support level of 1.98, suggesting suitability for range-bound swing trading. The analysis also includes a breakdown of buy, sell, and neutral signals from indicators like MACD, RSI, and different moving averages.
2026-08-07 05:11:27
OmniAb Inc (OABI) reported strong Q2 2026 results with a 243% revenue surge to $13.4 million, driven by higher milestone revenue and two programs advancing directly from Phase 1 to Phase 3. The company, which uses a unique transgenic chicken platform for human antibody sequences, improved its net loss to $5.9 million and raised its full-year revenue guidance to $32 million-$36 million. Despite reliance on milestone payments and operating at a net loss, OmniAb is seeing strong interest in its technologies and expects long-term growth through royalties and an expanding exploration platform.
2026-08-06 22:11:28
OmniAb Inc. (NASDAQ:OABI) reported a significant 244% year-over-year revenue increase in Q2 2026, reaching $13.4 million, primarily driven by milestone payments and the xPloration instrument platform. This strong performance led the company to raise its full-year 2026 revenue guidance to $32 million to $36 million and improve its year-end cash balance outlook. OmniAb also expanded its partner network to 110 active partners and increased its clinical-stage pipeline to 34 programs, underscoring robust growth in its antibody discovery business.
2026-08-06 20:11:28
OmniAb Inc. reported a significant increase in revenue for Q2 and H1 2026, driven by license and milestone payments, while simultaneously reducing its net loss and cash burn from operations. The company expanded its partner base to 110 active partners and 425 active programs, reinforcing its financial stability with $52.0 million in cash and equivalents, sufficient to fund operations for at least 12 months. Despite a $2.9 million impairment charge on an intangible asset, OmniAb's strategic focus on its technology platform and partnerships is yielding positive financial improvements.
